This HTML5 document contains 147 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33385353
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu en 2009 mokslinis straipsnis vitskapeleg artikkel наукова стаття, опублікована в жовтні 2009 บทความทางวิทยาศาสตร์ artículo científico publicado en 2009 2009年論文 teaduslik artikkel tudományos cikk 2009年论文 naučni članak 2009年の論文 article scientific 2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած 2009年论文 scientific article article científic scienca artikolo мақолаи илмӣ 2009年論文 vědecký článek vedecký článok artikull shkencor научная статья vetenskaplig artikel artykuł naukowy artigo científico articol științific מאמר מדעי 2009年論文 wissenschaftlicher Artikel 2009年论文 bilimsel makale wetenschappelijk artikel 2009年论文 სამეცნიერო სტატია tieteellinen artikkeli article scientifique (publié 2009) 2009年論文 научни чланак 2009년 논문 мақолаи илмӣ سائنسی مضمون научна статия научни чланак επιστημονικό άρθρο vitenskapelig artikkel artigo científico (publicado na 2009) 2009年論文 videnskabelig artikel (udgivet 2009) 2009年论文 مقالة علمية 2009 nî lūn-bûn artigo científico (publicado na 2009) 2009年论文 artikulong pang-agham مقالهٔ علمی articolo scientifico 2009 թվականի հոտեմբերին հրատարակված գիտական հոդված ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bài báo khoa học
p:P577
wds:Q33385353-66ECF443-A83B-474B-8D5A-3B6690476767
wdt:P577
2009-10-01T00:00:00Z
p:P407
wds:Q33385353-28A78A29-9CB9-4A98-9E72-1B4FE06E28A9
wdt:P407
wd:Q1860
p:P2860
wds:Q33385353-F2075A18-C7A6-4C61-9B90-A64328B900F6 wds:Q33385353-F2ED4091-97F8-4C6A-9D46-BE69BF94AE54 wds:Q33385353-5C0CC94E-7CDB-4A70-A36C-41BB974A93D8 wds:Q33385353-D8DBD3E4-F886-4B7A-A5B7-03B706A4B255 wds:Q33385353-DAF57B93-81CB-440F-AADA-BB67204B40AB wds:Q33385353-20B9E4FB-3DA2-4923-9A42-EE6655D418A1 wds:Q33385353-2A3BFB27-5698-4CA7-902D-ECAB75CBCBDB wds:Q33385353-1B2C5751-1D7D-4333-B030-F699C8D51DDC wds:Q33385353-560F2851-9B4E-4374-B721-0DC2C96D3C8D wds:Q33385353-47A6FA53-711B-4F95-8311-78CF3805C1AB wds:Q33385353-09B1FBC6-4788-4E57-B1A7-E519BB6D08D1
wdt:P2860
wd:Q43864036 wd:Q52448919 wd:Q33773306 wd:Q33364359 wd:Q33364244 wd:Q45115068 wd:Q33372761 wd:Q44211035 wd:Q40634072 wd:Q80258993 wd:Q33364240
p:P2093
wds:Q33385353-0FD35803-2B1D-438B-BDDE-674B9C6AD504 wds:Q33385353-2A8EFEC9-DA14-465E-A06A-1150D096DF0A wds:Q33385353-4BB18908-DA28-45BA-9D45-0DB54E440757 wds:Q33385353-4DA1AAF8-F63C-45A5-9209-7C2018E9BE1C wds:Q33385353-6A3138F0-7E87-4E8D-83FD-F3DCBF80FC2E wds:Q33385353-7AAEBA66-28DF-4982-89A8-89E615D50A3D wds:Q33385353-CD23CB28-0DB1-42DC-A651-71DA8A2168C0 wds:Q33385353-EDB8C5E1-96BC-4646-A11E-ECB8DEBE58D8 wds:Q33385353-F036F49C-52DA-4E3A-BC54-3B6C7582C959
wdt:P2093
Christian Gisselbrecht Nicolas Mounier Marjan Ertault Jean-Baptiste Golfier Pauline Brice Christophe Ferme Vincent Ribrag Josette Briere Gilles Salles
rdfs:label
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA
skos:prefLabel
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA
schema:name
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA
p:P50
wds:Q33385353-527FAF9D-0EAC-4407-B3B8-18F51FB89324
wdt:P50
wd:Q59200159
p:P1476
wds:Q33385353-7C4688C9-52F8-4E79-9F46-8ECD7ED34EA1
wdt:P1476
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA
p:P304
wds:Q33385353-D7F0464B-600A-46BD-BDCF-800EE0EDCC99
wdt:P304
4540-4546
p:P31
wds:Q33385353-17C9EEDC-E60C-46D4-86AA-F0298B2CFEC9
wdt:P31
wd:Q13442814
p:P921
wds:Q33385353-18468C23-0E20-4E6D-B4CE-F5E07214082C wds:Q33385353-63A44B61-CD02-4C86-A914-5A44A6FBB0E4 wds:Q33385353-93B2960B-C057-49BE-8FAB-44CF1186C5A8 wds:Q33385353-30172113-76FA-4172-ABAE-3A4B92DBA71A wds:Q33385353-4FBB0B22-7ABA-4FC0-938B-7491C2C2D0DB
wdt:P921
wd:Q18936 wd:Q18557022 wd:Q42824440 wd:Q4833719 wd:Q412323
p:P698
wds:Q33385353-E3BF6FB7-E6F6-40AA-A8BC-8044FEE350F0
wdtn:P698
n10:19593797
wdt:P698
19593797
p:P1433
wds:Q33385353-C8954225-3E61-4759-A48A-46BD558D132C
wdt:P1433
wd:Q326041
p:P433
wds:Q33385353-1B80C525-0332-474B-B0F0-4CF1DCC2CEBA
p:P478
wds:Q33385353-BFB664FA-6411-408E-8B89-651FCB374645
wdt:P433
19
wdt:P478
115
p:P356
wds:Q33385353-4B837CD8-B51B-4B97-946E-F019261E30A1
wdtn:P356
n11:CNCR.24518
wdt:P356
10.1002/CNCR.24518
p:P5875
wds:Q33385353-5E35EE5E-F232-427B-B510-8D75CF4DF10F
wdt:P5875
26662680